AUAUniversity

Update Series (2026) Lesson 18: Testosterone Therapy: Is It Safe? A Case-Based Approach Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

AUA Guidelines: Advanced Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Kristen R. Scarpato, MD, MPH To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer

AUA2026: Focus on: Metastatic Urothelial Carcinoma CME Available: https://cme.auanet.org/URL/FOCUS264ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Select appropriate first-line therapies for patients with locally advanced or metastatic urothelial carcinoma during initial treatment planning, in accordance with updated NCCN guidelines. 2. Evaluate holistic management approaches, including treatment sequencing, therapy transitions, and long-term follow-up for patients with locally advanced or metastatic urothelial carcinoma throughout the course of disease. 3. Implement strategies to recognize, monitor, and mitigate treatment-related adverse events in patients receiving systemic therapy for locally advanced or metastatic urothelial carcinoma. 4. Integrate shared decision-making tools and communication strategies into clinical practice to ensure alignment of treatment choices with patient values and caregiver input. 5. Distinguish between treatment pathways for different stages of advanced bladder cancer, including variant histologies to ensure accurate staging and appropriate therapy selection based on the latest NCCN guidelines. ACKNOWLEDGEMENTS Support provided by independent educational grants from: Merck & Co., Inc. Pfizer, Inc.

AUA Guidelines: Clinically Localized Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: James Eastham, MD, FACS To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/clinically-localized-prostate-cancer

Update Series (2026): Kidney Stones and the Infected Patient Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Mantu Gupta, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Focus on: Biomarkers, MRI and PSMA PET Imaging in Prostate Cancer Webcast CME Available: https://cme.auanet.org/URL/FOCUS262ONL LEARNING OBJECTIVES: After participating in this CME activity, participants will be able to: 1. Critically appraise recent developments in imaging biomarkers and molecular diagnostics (e.g., genomic risk scores, liquid biopsy) and discuss how they complement MRI and PSMA PET in prostate cancer care. 2. Determine the optimal clinical scenarios (diagnostic, staging, recurrence, surveillance) in which PSMA PET/CT or PET/MRI adds value beyond conventional imaging. 3. Recognize potential pitfalls in PSMA PET interpretation — including false positives, false negatives, non–PSMA-expressing disease, and technical artifacts — and implement strategies to mitigate them. 4. Synthesize biomarker, MRI, and PSMA PET findings into a personalized management plan, including guiding biopsy, focal therapy, salvage therapy, or systemic treatments. 5. Select appropriate patients with radiorecurrent or organ-confined prostate cancer for advanced imaging and guide re-treatment decisions (e.g., salvage therapy, targeted radiotherapy). ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Blue Earth Diagnostics, Inc. Lantheus Medical Imaging

AUA2026 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team CME Available: https://cme.auanet.org/URL/PARP26ONL LEARNING OBJECTIVES: At the conclusion of this CME activity, participants will be able to: 1. Integrate biomarker and genetic testing principles into clinical workflows for patients with metastatic prostate cancer, including when to order testing, how to interpret HRR mutation results (inclusive of BRCA and non-BRCA), and how to address barriers to testing through multidisciplinary coordination. 2. Explain the mechanism of action of PARP inhibitors and the biological and clinical rationale for their use—both as monotherapy and in combination approaches—in the treatment of mPC. 3. Evaluate emerging efficacy and safety data on PARPi combinations, including patient subgroup analyses, sequencing strategies, and the role of combination therapy in different stages of mPC. 4. Apply best practices for side effect monitoring and mitigation in patients receiving PARP inhibitors alone or in combination, leveraging the multidisciplinary team for optimal therapy management and patient quality of life. 5. Implement guideline-concordant care strategies in practice, including genetic testing workflow implementation, coordination among care team members, and patient engagement in shared decision-making and clinical trial enrollment. 5. Utilize current evidence-based guidelines to select and sequence PARP inhibitor therapy for patients with mPC, optimizing oncologic outcomes while individualizing care based on molecular profile and patient-specific factors. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astrazeneca Merck & Co., Inc Pfizer, Inc.

Update Series (2026) Lesson 15: Case-Based Testicular Cancer Clinical Practice Guidelines Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit cme.auanet.org/URL/US2026

AUA Guidelines: Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Jaspreet S. Sandhu, MD To access the full guideline, please use the following link: https://www.auanet.org/guidelines-and-quality/guidelines/bph-guideline. Please note that access to the full guideline requires user login. If you do not already have an account, you can create a free login.

AUA2026: Society of Women in Urology Meeting Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Amy N. Luckenbaugh, MD, FACS To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA2026: Society of Urologic Oncology Meeting Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Dr. Kelvin A. Moses, MD, PhD & Dr. Mark A. Preston, MD, MPH To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA2026: Society of Benign Prostate Disease Meeting Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Kevin Thomas McVary, MD, FACS To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA Guidelines: Early Detection of Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Simpa Salami, MD, MPH Lin DW, Carlsson S, Filson CP, et al. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026).J Urol. 0(0).10.1097/JU.0000000000004995. https://www.auajournals.org/doi/10.1097/JU.0000000000004995

AUA2026: Sexual Medicine Society of North America Meeting Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Landon Trost, MD, To register for AUA2026, please visit auanet.org/AUA2026/register!

AUA2026: Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Meeting Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Anne Pelletier Cameron, MD, URPS To register for AUA2026, please visit auanet.org/AUA2026/register!

Update Series (2026): At-Home Diagnostic and Therapeutic Options in Men's Health Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Richard J. Fantus, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Research Programming Preview: Amplifying the Impact of Research for Career Development Host: H. Henry Lai, MD Guest: Naveen Kachroo, MD, PhD Joining us today for this special episode brought to you by the AUA Office of Research, Research Education Committee, are Drs. H. Henry Lai and Naveen Kachroo discussing the dynamic research education programming planned at AUA2026. Head to auanet.org/AUA2026/register to check out the new and exciting programming at AUA2026 and to register!

Update Series (2026): Perioperative Management of Urinary Diversion: What Every Urologist Should Know Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Rohit Reddy, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AUA2026: Advanced Cystoscopy Training for APPs Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Brett Johnson, MD and Davis Viprakasit, MD, FACS Tune in to hear straight from the experts about our newest Hands-On Skills Training offering - Advanced Cystoscopy Training for APPs, part of the pre-meeting programming at AUA2026! In this episode, Dr. Brett Johnson and Dr. Davis Viprakasit discuss all about what you can expect from the Advanced Cystoscopy Training for APPs, a new APP hands-on skills training being held at AUA2026. This training provides both a half-day of hands-on skills training in the most critical procedural areas of need for APPs, as well as a library of on-demand virtual didactics straight from the experts. Spaces are still available - for more information or to register, please visit https://www.auanet.org/AUA2026/program/pre-meeting-programs Outline: Segment #1: Why offer the Advanced Cystoscopy Training for APPs? Segment #2: Description of the course Segment #3: Unique aspects of the course Segment #4: Potential benefits to participants Segment #5: Future directions

LG-IR-NMIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Chad R. Ritch, MD, MBA, FACS CME Available: cme.auanet.org/URL/GUPOD251 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning. 2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC. 3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.

NMIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Janet Kukreja, MD, MPH, FACS CME Available: https://cme.auanet.org/URL/GUPOD253 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs. 2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence. 3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.

MIBC Treatment Landscape (Republished) Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Jen-Jane Liu, MD, FACS CME Available: https://cme.auanet.org/URL/GUPOD252 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors. 2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning. 3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.

AUA2025: Key Takeaways: Bladder Cancer Presenters: Patrick Hensley, MD & Janet Kukreja, MD

Update Series (2026) Lesson 5: Long-term Urinary Catheters: Their Role & Management of Complications Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit https://cme.auanet.org/URL/US2026

Adjuvant Therapy for Renal Cell Carcinoma Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Daniel Shapiro, MD, FACS CME Available: https://cme.auanet.org/URL/RCCPOD261 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from: Merck & Co., Inc. LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Define adjuvant therapy, review current clinical guidelines, and recognize the current landscape of treatment options for patients with RCC. 2. Compare and contrast different adjuvant therapies available for RCC, including targeted therapies and immunotherapies. 3. Identify common side effects associated with adjuvant therapies for RCC and provide strategies for managing and mitigating these adverse events in clinical practice. 4. Discuss ongoing clinical trials and new therapeutic targets under investigation for adjuvant treatment of RCC.

Use of Suction Ureteroscopes for Kidney Stone Treatment: CVAC System Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Karen L. Stern, MD

Update Series: The Role of Nephrectomy in Advanced Kidney Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Sarah P. Psutka, M.D., M.S., F.A.C.S. Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

AI for Prostate Cancer Treatment Planning  Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Wayne G. Brisbane, MD

AUA Guidelines: Salvage Therapy for Prostate Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Yaw Nyame, MD, MS, MBA Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211(4):509-517. https://www.auajournals.org/doi/10.1097/JU.0000000000003892 Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy. J Urol. 2024;211(4):518-525. https://www.auajournals.org/doi/10.1097/JU.0000000000003891 Morgan TM, Boorjian SA, Buyyounouski MK, et al. Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part III: salvage therapy after radiotherapy or focal therapy, pelvic nodal recurrence and oligometastasis, and future directions. J Urol. 2024;211(4):526-532. https://www.auajournals.org/doi/10.1097/JU.0000000000003890

AUA Guidelines: Diagnosis and Management of Male Chronic Pelvic Pain Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Elise JB De, MD & Dane Johnson, MD Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part I Evaluation and Management Approach. J Urol. 0(0). doi:10.1097/JU.0000000000004564. https://www.auajournals.org/doi/10.1097/JU.0000000000004564 Lai HH, Pontari MA, Argoff CE, et al. Male Chronic Pelvic Pain: AUA Guideline: Part II Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. J Urol. 0(0). doi:10.1097/JU.0000000000004565. https://www.auajournals.org/doi/10.1097/JU.0000000000004565 Lai HH, Pontari MA, Argoff CE, at al. Male Chronic Pelvic Pain: AUA Guideline: Part III Treatment of Chronic Scrotal Content Pain. J Urol. 0(0). doi:10.1097/JU.0000000000004566. https://www.auajournals.org/doi/10.1097/JU.0000000000004566

NMIBC Treatment Landscape Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Janet Kukreja, MD, MPH, FACS CME Available: https://cme.auanet.org/URL/GUPOD253 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs. 2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence. 3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.

MIBC Treatment Landscape Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Jen-Jane Liu, MD, FACS CME Available: auau.auanet.org/node/44077 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Integrate immunotherapy and targeted therapy into the multimodal management of MIBC, selecting appropriate regimens and sequencing strategies based on current guidelines, clinical trial data, and patient-specific factors. 2. Evaluate the clinical role, mechanisms of action, and evidence base for targeted therapies in MIBC, including biomarker-driven selection to support personalized treatment planning. 3. Develop and apply practical approaches for preventing, monitoring, and managing immune-related adverse events and other toxicities associated with immunotherapy and targeted therapy to optimize patient safety, adherence, and quality of life.

AUA Guidelines: Genitourinary Syndrome of Menopause  Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Tracey S. Wilson, MD & Una J. Lee, MD Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025) Kaufman MR, Ackerman LA, Amin KA, et al. The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause. J Urol. 0(0). doi:10.1097/JU.0000000000004589. https://www.auajournals.org/doi/10.1097/JU.0000000000004589

LG-IR-NMIBC Treatment Landscape Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Chad R. Ritch, MD, MBA, FACS CME Available: https://cme.auanet.org/URL/GUPOD251 ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Johnson & Johnson LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Differentiate between traditional and emerging intravesical therapies for LG-IR-NMIBC, considering mechanism of action, administration schedules, and patient eligibility to support individualized treatment planning. 2. Incorporate into practice shared decision-making strategies that align clinical recommendations with patient values, preferences, and quality-of-life considerations in the management of LG-IR-NMIBC. 3. Utilize practical approaches for integrating intravesical therapy into routine clinical workflows, including coordination among multidisciplinary teams, patient education, and follow-up to optimize adherence and outcomes.

Core Curriculum: Surgical Management of Urolithiasis AUA Urology Core Curriculum: auau.auanet.org/core Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Marcelino E. Rivera, MD and T. Max Shelton, MD Outline: Segment 1: Acute Stone Event and Radiographic Evaluation Segment 2: Shock Wave Lithotripsy Segment 3: Ureteroscopy Segment 4: Percutaneous Nephrolithotomy Segment 5: Intracorporeal Lithotripsy Segment 6: Special Considerations

AUA2025: Key Takeaways: BPH Presenters: Bilal Chughtai, MD & Dean S. Elterman, MD, MSc, FRCSC

AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS

AUA Guidelines: Recurrent Uncomplicated Urinary Tract Infections in Women Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: A. Lenore Ackerman, MD, PhD & Melissa R. Kaufman, MD, PhD Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025) Ackerman AL, Bradley M, D’Anci KE, Hickling D, Kim SK, Kirkby E. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004723

Anorectal Malformation AUA Urology Core Curriculum: auau.auanet.org/core Host: Mark L. Gonzalgo, MD, PhD, MBA Guests: Christina Ho, MD and Molly E. Fuchs, MD Outline: Segment 1: Anorectal Malformation Overview/Background Segment 2: Initial Evaluation and Management Segment 3: Cloacal Malformations Segment 4: Long-Term Bladder Management & Concern for CKD Segment 5: Other Considerations

AUA2025: Key Takeaways: Endourology/Stones Highlights Presenters: Davis Viprakasit, MD & Stephen Nakada MD, FACS, FRCS

Update Series (2025) Lesson 30: Beyond Ureteropelvic Junction: Case-Based Tips and Tricks in Robotic Ureteral Stricture Reconstructive Surgery Now in its 44th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit AUAnet.org/Update25

The Latest Breakthroughs in LG-IR-NMIBC (2025) CME Available: auau.auanet.org/node/43689 After participating in this CME activity, participants will be able to: 1. Apply updated clinical evidence and treatment protocols for low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC) in appropriate patient cases to reduce recurrence rates and improve clinical outcomes. 2. Improve clinical decision-making related to risk stratification and surveillance strategies for low-grade, intermediate-risk NMIBC based on pathophysiology, epidemiology, and progression patterns. 3. Support evidence-based, patient-centered treatment selection options for low-grade, intermediate-risk NMIBC by comparing traditional intravesical therapies with emerging treatments. 4. Interpret the efficacy and safety profiles of new therapies to appropriately integrate new therapeutic options into clinical practice (upon regulatory approval). 5. Utilize new medications in the evolving treatment landscape following an evaluation of key clinical trial data from recent studies. 6. Assess the impact of treatment options on patient-reported outcomes, including quality of life and treatment burden, to guide shared decision-making and optimize care delivery. ACKNOWLEDGEMENTS Support provided by an independent educational grant from: UroGen Pharma, Inc.

The Latest Breakthroughs in mHSPC CME Available: https://auau.auanet.org/node/43825 After participating in this CME activity, participants will be able to: 1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC. 2.Implement current clinical guidelines for biomarker testing in mHSPC. 3.Explain the role of the PI3K/AKT pathway in prostate cancer biology. 4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC. 5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC. Acknowledgements: AstraZeneca Bayer HealthCare Pharmaceuticals Inc.

AUA2025: Key Takeaways: Sexual Dysfunction Highlights Presenter: Brittany Berk, MD & Arthur Burnett, MD, MBA

AUA2025: Key Takeaways: Female Urology Highlights Presenter: Mitch G. Goldenberg, MD & Kathleen Kobashi, MD, MBA, FACS

AUA2025: John Duckett Memorial Lecture: Obstructive Bladder Disease: Molecular Insights and Therapeutic Opportunities Presenter: Rosalyn M. Adam, PhD

AUA2025: Ramon Guiteras Lecture: The Future of Healthcare: How Will Urology be Impacted? Presenter: Vin Gupta, MD, MPA

AUA2025: John K Lattimer Lecture: Telesurgery Presenter: Vipul Patel, MD

Contemporary Management of MIBC and Beyond: Expert Guidance for Urologists (Republished) CME Available: auau.auanet.org/node/42040 After participating in this CME activity, participants will be able to: 1. Describe the multimodal treatment approach for MIBC, including surgery, radiation therapy, and chemotherapy. 2. Analyze the role of neoadjuvant and adjuvant therapies, including chemotherapy, immunotherapy, and antibody drug conjugates, in improving patient outcomes. 3. Utilize knowledge of checkpoint inhibitors and antibody drug conjugates with their mechanisms of action to interpret the role of immunotherapy in the treatment of metastatic urothelial carcinoma. 4. Examine ongoing clinical trials and emerging treatments that are shaping the future of metastatic urothelial carcinoma management. 5. Employ appropriate patient and family education strategies regarding MIBC and metastatic urothelial carcinoma, treatment options, and expected outcomes. Acknowledgements Support provided by an independent educational grant from: Astellas and Pfizer, Inc.

AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs) CME Available: https://auau.auanet.org/node/43009 At the conclusion of this activity, participants will be able to: 1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy. 2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy. 3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer. 4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer. 5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy. ACKNOWLEDGEMENTS: This educational activity is supported by independent educational grants from: Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.